RESUMEN
BACKGROUND: Levetiracetam (LEV, 5-100 mg/kg) has been shown to prevent audiogenic seizures in a dose-dependent manner. This chemical is known to bind to synaptic vesicle protein 2A and inhibit l-type calcium channels, affecting neurotransmitter release. We hypothesize that the drug prevents audiogenic seizures partially by affecting cochlear neural response. METHODS: To test this hypothesis, rats were given 1000, 500, 50, or 0 mg/kg (saline control) LEV-injection. Distortion product otoacoustic emissions (DPOAE), reflecting outer hair cell (OHC) function, and cochlear compound action potentials (CAP), reflecting cochlear neural output, were recorded and compared pre- and post-LEV. RESULTS: 1000 mg/kg LEV-injection did not significantly affect DPOAE. The high dose LEV-injection, however, significantly reduced CAP amplitude resulting threshold shift (TS), prolonged CAP latency, and enhanced CAP forward masking. CAP latency and forward masking were significantly affected at the 500 mg/kg dose, but CAP-TS remained unchanged after LEV-injection. Interestingly, CAP latency wassignificantly prolonged, at least at the low stimulation levels, although the amplitude of CAP remained constant after a clinical dose of LEV-injection (50 mg/kg). DISCUSSION: Since the clinical dose of LEV-injection does not reduce CAP amplitude, the reduction of cochlear neural output is unlikely to be the underlying mechanism of LEV in the treatment of audiogenic seizure. The delayed cochlear neural response may be partially related to the prevention of audiogenic seizure. However, neuropharmacological changes in the central nervous system must play a major role in the treatment of audiogenic seizure, as it does in the treatment of focal epilepsy.
Asunto(s)
Epilepsia Refleja , Piracetam , Animales , Anticonvulsivantes/farmacología , Anticonvulsivantes/uso terapéutico , Epilepsia Refleja/metabolismo , Levetiracetam , Piracetam/metabolismo , Piracetam/farmacología , Ratas , Vesículas SinápticasRESUMEN
The present studies were conducted to show the potential of 2D zeolites as effective and non-toxic carriers of drugs. Layered zeolites exhibit adjustable interlayer porosity which can be exploited for controlled drug delivery allowing detailed investigation of the drug release because the structure of the carrier is known exactly. This study was conducted with model drugs ciprofloxacin and piracetam, and ZSM-55 with ca 1 nm thick layers, in detemplated and pillared forms. The release profiles differed from the commercial, crystalline forms of drugs-the release rate increased for ciprofloxacin and decreased for piracetam. To understand the dissolution mechanisms the release data were fitted to Korsmeyer-Peppas equation, showing Fickian (for pillared) and anomalous (for detemplated sample) transport. FT-IR studies showed that strong interaction carrier-drug may be responsible for the modified, slowed down release of piracetam while better solubility and faster release of ciprofloxacin was attributed to formation of the protonated form resulting in weaker interaction with the zeolite than in the pure crystalline form. Two independent tests on L929 mice fibroblasts (ToxiLight and PrestoBlue) showed that ZSM-55, in moderate concentrations may be safely used as a carrier of drug molecules, not having negative effect on the cells viability or proliferation rate.
Asunto(s)
Ciprofloxacina/química , Portadores de Fármacos/química , Zeolitas/química , Animales , Línea Celular , Supervivencia Celular/efectos de los fármacos , Ciprofloxacina/metabolismo , Portadores de Fármacos/farmacología , Liberación de Fármacos , Ratones , Piracetam/química , Piracetam/metabolismo , Zeolitas/farmacologíaRESUMEN
Piracetam (2-oxo-1-pyrrolidine acetamide) is a popular cognitive enhancer, which has recently been detected in waste and drinking water. Nootropic drugs are designed to affect human metabolism and act on the nervous system, but their environmental effects have yet to be the subject of detailed studies. In this report, we present the efficient biodegradation of the cognitive enhancer, piracetam. Two bacterial strains capable of using this compound as the sole carbon source were isolated and later identified as Ochrobactrum anthropi strain MW6 and Ochrobactrum intermedium strain MW7. The compound's mineralization and the cleavage of the heterocyclic ring were shown in the experiments with 14C-labeled piracetam. This is also the first report of a pharmaceutical's degradation by the Ochrobactrum genus. This study presents model microorganisms that can be used in further investigation of piracetam's degradation pathways as well as enzymes and genes involved in the process.
Asunto(s)
Nootrópicos/metabolismo , Ochrobactrum/metabolismo , Piracetam/metabolismo , Cromatografía Líquida de Alta Presión , Ochrobactrum/crecimiento & desarrollo , Ochrobactrum/aislamiento & purificación , Piracetam/análisisRESUMEN
BACKGROUND: Previous findings revealed high correlations between serum/plasma and saliva levetiracetam concentrations, indicating saliva as an alternative matrix for monitoring levetiracetam therapy. Levetiracetam concentration in the hair, which could reflect long-term drug exposure and patients' compliance, has not been systematically tested, as yet. The aim of this study was to determine the correlation between plasma, saliva, and hair levetiracetam concentrations in 47 patients with epilepsy. METHODS: Plasma, saliva, and hair levetiracetam concentrations were measured by liquid chromatography-tandem mass spectrometry with positive ionization. RESULTS: Levetiracetam saliva and plasma concentrations were highly correlated (r = 0.93). Plasma concentrations were not influenced by sex, age, and other concomitant antiepileptic drugs. Levetiracetam hair concentrations correlated with plasma concentrations (r = 0.36) but not daily dose (mg/kg). Drug hair concentrations were not influenced by hair color or treatment (dyed). CONCLUSIONS: The results tend to indicate that saliva may be a reliable alternative to plasma for monitoring levetiracetam concentrations. Levetiracetam can also be detected in human hair.
Asunto(s)
Cabello/química , Piracetam/análogos & derivados , Plasma/química , Saliva/química , Adolescente , Adulto , Anticonvulsivantes/sangre , Anticonvulsivantes/metabolismo , Anticonvulsivantes/uso terapéutico , Cromatografía Liquida/métodos , Monitoreo de Drogas/métodos , Epilepsia/sangre , Epilepsia/tratamiento farmacológico , Epilepsia/metabolismo , Femenino , Humanos , Levetiracetam , Masculino , Persona de Mediana Edad , Piracetam/sangre , Piracetam/metabolismo , Piracetam/uso terapéutico , Espectrometría de Masas en Tándem/métodos , Adulto JovenAsunto(s)
Anticonvulsivantes/metabolismo , Enfermedad Crítica/terapia , Hemofiltración/métodos , Tasa de Depuración Metabólica/fisiología , Piracetam/análogos & derivados , Anciano , Anticonvulsivantes/administración & dosificación , Relación Dosis-Respuesta a Droga , Circulación Extracorporea/métodos , Hemofiltración/tendencias , Humanos , Levetiracetam , Masculino , Tasa de Depuración Metabólica/efectos de los fármacos , Piracetam/administración & dosificación , Piracetam/metabolismoRESUMEN
Newly established TLC-densitometric and RP-HPLC methods were developed and validated for the simultaneous determination of Piracetam (PIR) and Vincamine (VINC) in their pharmaceutical formulation and in the presence of PIR and VINC degradation products, PD and VD, respectively. The proposed TLC-densitometric method is based on the separation and quantitation of the studied components using a developing system that consists of chloroform-methanol-glacial acetic acid-triethylamine (8 + 2 + 0.1 + 0.1, v/v/v/v) on TLC silica gel 60 F254 plates, followed by densitometric scanning at 230 nm. On the other hand, the developed RP-HPLC method is based on the separation of the studied components using an isocratic elution of 0.05 M KH2PO4 (containing 0.1% triethylamine adjusted to pH 3 with orthophosphoric acid)-methanol (95 + 5, v/v) on a C8 column at a flow rate of 1 mL/min with diode-array detection at 230 nm. The developed methods were validated according to International Conference on Harmonization guidelines and demonstrated good accuracy and precision. Moreover, the developed TLC-densitometric and RP-HPLC methods are suitable as stability-indicating assay methods for the simultaneous determination of PD and VD either in bulk powder or pharmaceutical formulation. The results were statistically compared with those obtained by the reported RP-HPLC method using t- and F-tests.
Asunto(s)
Densitometría , Piracetam/análisis , Piracetam/metabolismo , Vincamina/análisis , Vincamina/metabolismo , Cromatografía Líquida de Alta Presión , Cromatografía en Capa Delgada , Estabilidad de Medicamentos , Estructura Molecular , Piracetam/química , Vincamina/químicaRESUMEN
INTRODUCTION: Development of a selective and specific high affinity PET tracer, [(11)C]UCB-A, for the in vivo study of SV2A expression in humans. Radiochemistry and preclinical studies in rats and pigs including development of a tracer kinetic model to determine VT. A method for the measurement of percent intact tracer in plasma was developed and the radiation dosimetry was determined in rats. RESULTS: 3-5GBq of [(11)C]UCB-A could be produced with radiochemical purity exceeding 98% with a specific radioactivity of around 65GBq/µmol. In vitro binding showed high selective binding towards SV2A. [(11)C]UCB-A displayed a dose-dependent and reversible binding to SV2A as measured with PET in rats and pigs and the VT could be determined by Logan analysis. The dosimetry was favorable and low enough to allow multiple administrations of [(11)C]UCB-A to healthy volunteers, and the metabolite analysis showed no sign of labeled metabolites in brain. CONCLUSIONS: We have developed the novel PET tracer, [(11)C]UCB-A, that can be used to measure SV2A expression in vivo. The dosimetry allows up to 5 administrations of 400MBq of [(11)C]UCB-A in humans. Apart from measuring drug occupancy, as we have shown, the tracer can potentially be used to compare SV2A expression between individuals because of the rather narrow range of baseline VT values. This will have to be further validated in human studies.
Asunto(s)
Radioisótopos de Carbono , Glicoproteínas de Membrana/metabolismo , Proteínas del Tejido Nervioso/metabolismo , Piracetam/análogos & derivados , Tomografía de Emisión de Positrones/métodos , Animales , Encéfalo/diagnóstico por imagen , Encéfalo/metabolismo , Levetiracetam , Masculino , Piracetam/química , Piracetam/metabolismo , Piracetam/farmacocinética , Ratas , Porcinos , Distribución TisularRESUMEN
OBJECTIVE: To determine if levetiracetam (LEV) enhances the impact in excitatory presynaptic terminals of a rate-limiting mechanism in vesicle trafficking termed supply rate depression that emerges to limit synaptic transmission during heavy, epileptiform use. METHODS: The effect of LEV was measured with electrophysiologic assays of monosynaptic connections in ex vivo hippocampal slices from wild-type and synapsin knockout mice, and in primary cell culture neurons from wild-type and synaptic vesicle glycoprotein 2a (SV2a) knockout mice. RESULTS: LEV enhanced the impact of supply rate depression at Schaffer collateral synapses by shortening the time course for induction. The LEV effect was selective for supply rate depression because other presynaptic vesicle trafficking mechanisms were not affected. The half maximal effective concentration (EC50 ) was ~50 µm. The maximal effect was ~15% and occurred at 100 µm, which is a clinically relevant concentration. An experimental protocol is established for distinguishing atypical antiepileptic drugs (AEDs) that affect supply rate depression, such as LEV, from typical AEDs, such as carbamazepine, that affect upstream mechanisms. The LEV effect was abolished at synapses from knockout mice lacking SV2a and from synapses lacking synapsin 1 and 2. SIGNIFICANCE: The findings are consistent with the new hypothesis that LEV acts to treat epilepsy by accelerating the induction of supply rate depression at excitatory synapses during incipient epileptic activity. The absence of the effect in the knockouts confirms that presynaptic function is the target. More specifically, the absence in SV2a knockouts is consistent with previous binding studies suggesting that SV2a is the target for LEV. The absence in synapsin knockouts indicates that the phenotypic target intersects with the biochemical pathway that is altered in synapsin knockouts. The results from synapsin knockouts additionally suggest that development of functional analogs with increased potency might be possible because induction of supply rate depression is faster in synapsin knockouts compared to wild-type synapses treated with LEV.
Asunto(s)
Depresión Sináptica a Largo Plazo/efectos de los fármacos , Piracetam/análogos & derivados , Vesículas Sinápticas/efectos de los fármacos , Vesículas Sinápticas/metabolismo , Animales , Animales Recién Nacidos , Hipocampo/efectos de los fármacos , Hipocampo/metabolismo , Levetiracetam , Depresión Sináptica a Largo Plazo/fisiología , Ratones , Ratones Noqueados , Técnicas de Cultivo de Órganos , Piracetam/metabolismo , Piracetam/farmacología , Transporte de Proteínas/efectos de los fármacos , Transporte de Proteínas/fisiologíaRESUMEN
The putative Major Facilitator Superfamily (MFS) transporter, SV2A, is the target for levetiracetam (LEV), which is a successful anti-epileptic drug. Furthermore, SV2A knock out mice display a severe seizure phenotype and die after a few weeks. Despite this, the mode of action of LEV is not known at the molecular level. It would be extremely desirable to understand this more fully in order to aid the design of improved anti-epileptic compounds. Since there is no structure for SV2A, homology modelling can provide insight into the ligand-binding site. However, it is not a trivial process to build such models, since SV2A has low sequence identity to those MFS transporters whose structures are known. A further level of complexity is added by the fact that it is not known which conformational state of the receptor LEV binds to, as multiple conformational states have been inferred by tomography and ligand binding assays or indeed, if binding is exclusive to a single state. Here, we explore models of both the inward and outward facing conformational states of SV2A (according to the alternating access mechanism for MFS transporters). We use a sequence conservation analysis to help guide the homology modelling process and generate the models, which we assess further with Molecular Dynamics (MD). By comparing the MD results in conjunction with docking and simulation of a LEV-analogue used in radioligand binding assays, we were able to suggest further residues that line the binding pocket. These were confirmed experimentally. In particular, mutation of D670 leads to a complete loss of binding. The results shed light on the way LEV analogues may interact with SV2A and may help with the on-going design of improved anti-epileptic compounds.
Asunto(s)
Anticonvulsivantes/metabolismo , Glicoproteínas de Membrana/química , Glicoproteínas de Membrana/metabolismo , Simulación de Dinámica Molecular , Mutagénesis Sitio-Dirigida , Proteínas del Tejido Nervioso/química , Proteínas del Tejido Nervioso/metabolismo , Piracetam/análogos & derivados , Homología de Secuencia de Aminoácido , Secuencia de Aminoácidos , Humanos , Levetiracetam , Glicoproteínas de Membrana/genética , Datos de Secuencia Molecular , Proteínas del Tejido Nervioso/genética , Piracetam/metabolismo , Unión Proteica , Estructura Secundaria de ProteínaRESUMEN
Quantitative determination of anti-epileptic drug concentrations is of great importance in forensic toxicology cases. Although the drugs are not usually abused, they are important post-mortem cases where the question of both lack of compliance and accidental or deliberate poisoning might be raised. In addition these drugs can be relevant for driving under the influence cases. A reversed phase ultra-performance liquid chromatography-tandem mass spectrometry method has been developed for the quantitative analysis of the anti-epileptic compounds carbamazepine, carbamazepine-10,11-epoxide, gabapentin, lamotrigine, levetiracetam, oxcarbazepine, 10-OH-carbazepine, phenobarbital, phenytoin, pregabalin, and topiramate in whole blood, using 0.1 mL sample volume with methaqualone as internal standard. Sample preparation was a simple protein precipitation with acetonitrile and methanol. The diluted supernatant was directly injected into the chromatographic system. Separation was performed on an Acquity UPLC® BEH Phenyl column with gradient elution and a mildly alkaline mobile phase. The mass spectrometric detection was performed in positive ion mode, except for phenobarbital, and multiple reaction monitoring was used for drug quantification. The limits of quantification for the different anti-epileptic drugs varied from 0.064 to 1.26 mg/L in blood, within-day and day-to-day relative standard deviations from 2.2 to 14.7% except for phenobarbital. Between-day variation for phenobarbital was 20.4% at the concentration level of 3.5 mg/L. The biases for all compounds were within ±17.5%. The recoveries ranged between 85 and 120%. The corrected matrix effects were 88-106% and 84-110% in ante-mortem and post-mortem whole blood samples, respectively.
Asunto(s)
Anticonvulsivantes/sangre , Toxicología Forense/métodos , Espectrometría de Masas en Tándem/métodos , Aminas/sangre , Aminas/metabolismo , Anticonvulsivantes/metabolismo , Carbamazepina/análogos & derivados , Carbamazepina/sangre , Carbamazepina/metabolismo , Cromatografía Líquida de Alta Presión/métodos , Ácidos Ciclohexanocarboxílicos/sangre , Ácidos Ciclohexanocarboxílicos/metabolismo , Toxicología Forense/instrumentación , Gabapentina , Humanos , Levetiracetam , Oxcarbazepina , Piracetam/análogos & derivados , Piracetam/sangre , Piracetam/metabolismo , Ácido gamma-Aminobutírico/sangre , Ácido gamma-Aminobutírico/metabolismoRESUMEN
A simple liquid chromatography tandem mass spectrometry method was developed and validated according to the guidelines of the US Food and Drug Administration and the European Medicines Agency for a simultaneous quantification of levetiracetam (LEV) and its metabolite, UCB L057 in the plasma of patients. A 0.050 mL plasma sample was prepared by a simple and direct protein precipitation with 0.450 mL acetonitrile (ACN) containing 1 µg/mL of internal standard (IS, diphenhydramine), then vortex mixed and centrifuged. A 0.100 mL of the clear supernatant was diluted with 0.400 mL water and well mixed. A 0.010 mL of the resultant solution was injected into an Agilent Zorbax SB-C18 (2.1 mm×100 mm, 3.5 µm) column with an isocratic elution at 0.5 mL/min using a mixture of 0.1% formic acid in water and ACN (40:60 v/v). Detection was performed using an AB Sciex API 3000 triple quadrupole mass spectrometer, equipped with a Turbo Ion Spray source, operating in a positive mode: LEV at transition 171.1>154.1, UCB L057 at 172.5>126.1, and IS at 256.3>167.3; with an assay run time of 2 minutes. The lower limit of quantification (LLOQ) for both LEV and UCB L057 was validated at 0.5 µg/mL, while their lower limit of detection (LOD) was 0.25 µg/mL. The calibration curves were linear between 0.5 and 100 µg/mL for both analytes. The inaccuracy and imprecision of both intra-assay and inter-assay were less than 10%. Matrix effects were consistent between sources of plasma and the recoveries of all compounds were between 100% and 110%. Stability was established under various storage and processing conditions. The carryovers from both LEV and UCB L057 were less than 6% of the LLOQ and 0.13% of the IS. This assay method has been successfully applied to a population pharmacokinetic study of LEV in patients with epilepsy.
Asunto(s)
Cromatografía Liquida , Piracetam/análogos & derivados , Espectrometría de Masas en Tándem , Epilepsia/sangre , Humanos , Levetiracetam , Límite de Detección , Piracetam/sangre , Piracetam/metabolismo , Reproducibilidad de los ResultadosRESUMEN
The nature of the pharmacodynamic interactions of drugs is influenced by the drugs׳ mechanisms of action. It has been hypothesized that drugs with different mechanisms are likely to interact synergistically, whereas those with similar mechanisms seem to produce additive interactions. In this review, we describe an extensive investigation of the published literature on drug combinations of anticonvulsants, the nature of the interaction of which has been evaluated by type I and II isobolographic analyses and the subthreshold method. The molecular targets of antiepileptic drugs (AEDs) include Na(+) and Ca(2+) channels, GABA type-A receptor, and glutamate receptors such as NMDA and AMPA/kainate receptors. The results of this review indicate that the nature of interactions evaluated by type I isobolographic analyses but not by the two other methods seems to be consistent with the above hypothesis. Type I isobolographic analyses may be used not only for evaluating drug combinations but also for predicting the targets of new drugs.
Asunto(s)
Anticonvulsivantes/administración & dosificación , Anticonvulsivantes/metabolismo , Convulsiones/tratamiento farmacológico , Convulsiones/metabolismo , Animales , Anticonvulsivantes/química , Sitios de Unión/fisiología , Carbamazepina/administración & dosificación , Carbamazepina/química , Carbamazepina/metabolismo , Relación Dosis-Respuesta a Droga , Quimioterapia Combinada , Humanos , Piracetam/administración & dosificación , Piracetam/química , Piracetam/metabolismo , Resultado del TratamientoRESUMEN
Levtiracetam (Lev), an inhibitor of SV2A (synaptic vesicle protein A2), affected the ATP-dependent priming of Ca(2+)-regulated exocytosis in antral mucous cells of guinea pig. In antral mucous cells, the Ca(2+)-regulated exocytosis, which is activated by acetylcholine (ACh), consists of an initial peak that declines rapidly (initial phase) followed by a second slower decline (late phase). Dinitrophenol (DNP), which depletes ATP, inhibits the ATP-dependent priming. DNP abolished the initial phase by reducing the number of primed granules, Lev decreased the frequency of initial phase, but not in the presence of DNP. Moreover, 8-bromoguanosine 3'5'-cyclic monophosphate (8BrcGMP) accelerates the ATP-dependent priming. 8BrcGMP enhances the frequency of initial phase by increasing the number of primed granule. Lev added prior to 8BrcGMP addition decreased the frequency of initial phase, but Lev added after 8BrcGMP addition did not. Thus, Lev affected the granules in the process of priming, but it did not affect the granules already primed. Lev did not affect [Ca(2+)]i in unstimulated or ACh-stimulated antral mucous cells. Immunohistochemistry and western blotting demonstrated that SV2A exists in antral mucous cells. The results suggest that SV2A plays an essential role in maintaining the process of ATP-dependent priming in antral mucous cells. In conclusion, Lev decreases the frequency of Ca(2+)-regulated exocytosis the number of primed granules by inhibiting SV2A functions, leading to a decrease in antral mucous cells.
Asunto(s)
Calcio/metabolismo , Exocitosis/efectos de los fármacos , Mucosa Gástrica/citología , Glicoproteínas de Membrana/metabolismo , Piracetam/análogos & derivados , Acetilcolina/farmacología , Adenosina Trifosfato/metabolismo , Animales , Regulación de la Expresión Génica/efectos de los fármacos , Cobayas , Levetiracetam , Ligandos , Masculino , Piracetam/metabolismo , Piracetam/farmacología , Transporte de Proteínas/efectos de los fármacosRESUMEN
A rapid bioanalytical method was evaluated for the simultaneous determination of piracetam and its metabolite (M1) in human microsomal preparations by fast ultra-performance liquid chromatography/tandem mass spectrometry (UPLC-MS/MS). In addition, a validated method of M1 in rat plasma was developed and successfully applied on pharmacokinetic studies. The present study was carried out to determine the metabolic pathways of piracetam for phase I metabolism and used cytochrome P450 isoforms responsible for the piracetam metabolism in human liver microsomes (HLMs). While additional potential metabolites of piracetam were suggested by computer-modeling. The resulting 2-(2-oxopyrrolidin-1-yl) acetic acid was the sole metabolite detected after the microsomal treatment. The amide hydrolysis mainly underwent to form a metabolite i.e., 2-(2-oxopyrrolidin-1-yl) acetic acid (M1).
Asunto(s)
Microsomas Hepáticos/química , Piracetam/aislamiento & purificación , Piracetam/metabolismo , Animales , Cromatografía Líquida de Alta Presión , Humanos , Microsomas Hepáticos/metabolismo , Estructura Molecular , Piracetam/química , Piracetam/farmacocinética , Ratas , Ratas Wistar , Espectrometría de Masas en TándemRESUMEN
The aim of this study was to investigate the effect of Morin on the pharmacokinetics of Piracetam in rats, in vitro enzyme kinetics and metabolic stability (high throughput) studies using human liver microsomes in UPLC. For pharmacokinetics studies, male Wistar rats were pretreated with Morin (10 mg/kg) for one week and on the last day, a single dose of Piracetam (50 mg/kg) was given orally. In another group, both Morin and Piracetam were co-administered to evaluate the acute effect of Morin on Piracetam. The control group received oral distilled water for one week and administered with Piracetam on the last day. As Morin is an inhibitor of P- Glycoprotein (P-gp) and CYP 3A, it was anticipated to improve the bioavailability of Piracetam. Amazingly, relative to control, the areas under the concentration time curve and peak plasma concentration of Piracetam were 1.50- and 1.45-fold, respectively, greater in the Morin-pretreated group. However, co-administration of Morin had no significant effect on these parameters. Apart from the aforementioned merits, the results of this study are further confirmed by clinical trials; Piracetam dosages should be adjusted to avoid potential drug interaction when Piracetam is used clinically in combination with Morin and Morin-containing dietary supplements. The in vitro enzyme kinetics were performed to determined km, Vmax & CLins . The in vitro metabolic stability executed for the estimation of metabolic rate constant and half-life of Piracetam. These studies also extrapolate to in vivo intrinsic hepatic clearance (Clint, in vivo ) from in vitro intrinsic hepatic clearance (CLint, in vitro ).
Asunto(s)
Flavonoides/farmacocinética , Piracetam/farmacocinética , Administración Oral , Animales , Cromatografía Liquida/métodos , Interacciones Farmacológicas/fisiología , Flavonoides/administración & dosificación , Flavonoides/metabolismo , Humanos , Masculino , Microsomas Hepáticos/efectos de los fármacos , Microsomas Hepáticos/metabolismo , Piracetam/metabolismo , Ratas , Ratas WistarRESUMEN
BACKGROUND: Neonatal seizures can result in chronic epilepsy and long-term behavioral and cognitive deficits. Levetiracetam (LEV), an antiepileptic drug that binds to the synaptic vesicle protein 2A (SV2A), has been increasingly used off-label for the therapy of neonatal seizures. Preclinical data regarding the acute or long-term efficacy of LEV are lacking. METHODS: We tested the anticonvulsant efficacy of LEV in a rat model of hypoxia-induced neonatal seizures. In addition, we evaluated the protective effects of postnatal day (P)10 LEV treatment on later-life kainic acid (KA)-induced seizure susceptibility and seizure-induced neuronal injury. Western blot and immunohistochemistry were used to assess the developmental regulation of SV2A in the rat and human brain. RESULTS: LEV pretreatment at P10 significantly decreased the cumulative duration of behavioral and electrographic seizures at both 25 and 50 mg/kg. At P40, KA-induced seizures and neuronal loss were significantly diminished in rats previously treated with LEV. LEV target SV2A is present in both neonatal rat and human brain and increases steadily to adulthood. CONCLUSION: LEV suppressed acute seizures induced by perinatal hypoxia and diminished later-life seizure susceptibility and seizure-induced neuronal injury, providing evidence for disease modification. These results support consideration of a clinical trial of LEV in neonatal seizures.
Asunto(s)
Anticonvulsivantes/uso terapéutico , Piracetam/análogos & derivados , Convulsiones/tratamiento farmacológico , Convulsiones/prevención & control , Animales , Animales Recién Nacidos , Western Blotting , Encéfalo/metabolismo , Inmunohistoquímica , Ácido Kaínico/toxicidad , Levetiracetam , Glicoproteínas de Membrana/metabolismo , Proteínas del Tejido Nervioso/metabolismo , Piracetam/metabolismo , Piracetam/uso terapéutico , Ratas , Convulsiones/inducido químicamenteRESUMEN
The interaction of native calf thymus DNA with the drug levetiracetam (LV) has been investigated by absorption, emission, circular dichroism, melting temperature (T(m)) curves and viscosity studies. Spectrophotometric studies of the interaction of levetiracetam with DNA have shown that it can binds to CT-DNA and the DNA binding constant (K(b)=(4.9±0.2)×10(3) M(-1)) is comparable to groove binding drugs. Competitive fluorimetric studies with hoechst 33258 have shown that levetiracetam exhibit the ability to displace the DNA-bound hoechst 33258 indicating that it binds to DNA in strong competition with hoechst 33258 for the groove binding. Furthermore, the drug induces detectable changes in the CD spectrum of CT-DNA as well as changes in its viscosity. The values of melting temperature (T(m)) of DNA-methylene blue (MB) complex and LV-DNA-MB complex were determined. Finally, all of the experimental results prove that the minor groove binding must be predominant.
Asunto(s)
ADN/metabolismo , Piracetam/análogos & derivados , Animales , Unión Competitiva , Bisbenzimidazol , Bovinos , Dicroismo Circular , Cinética , Levetiracetam , Azul de Metileno/química , Desnaturalización de Ácido Nucleico , Piracetam/química , Piracetam/metabolismo , Espectrometría de Fluorescencia , Espectrofotometría Ultravioleta , Termodinámica , ViscosidadAsunto(s)
Anticonvulsivantes/metabolismo , Piracetam/análogos & derivados , Complicaciones del Embarazo/tratamiento farmacológico , Convulsiones/tratamiento farmacológico , Anticonvulsivantes/uso terapéutico , Femenino , Humanos , Levetiracetam , Piracetam/metabolismo , Piracetam/uso terapéutico , EmbarazoRESUMEN
Levetiracetam (LEV) is a prominent antiepileptic drug that binds to neuronal synaptic vesicle glycoprotein 2A protein and has reported effects on ion channels, but with a poorly defined mechanism of action. We investigated inhibition of voltage-dependent Ca(2+) (Ca(V)) channels as a potential mechanism through which LEV exerts effects on neuronal activity. We used electrophysiological methods to investigate the effects of LEV on cholinergic synaptic transmission and Ca(V) channel activity in superior cervical ganglion neurons (SCGNs). In parallel, we investigated the effects of the inactive LEV R-enantiomer, (R)-α-ethyl-2-oxo-1-pyrrolidine acetamide (UCB L060). LEV but not UCB L060 (each at 100 µM) inhibited synaptic transmission between SCGNs in long-term culture in a time-dependent manner, significantly reducing excitatory postsynaptic potentials after a ≥30-min application. In isolated SCGNs, LEV pretreatment (≥1 h) but not short-term application (5 min) significantly inhibited whole-cell Ba(2+) current (I(Ba)) amplitude. In current-clamp recordings, LEV reduced the amplitude of the afterhyperpolarizing potential in a Ca(2+)-dependent manner but also increased the action potential latency in a Ca(2+)-independent manner, which suggests additional mechanisms associated with reduced excitability. Intracellular LEV application (4-5 min) caused rapid inhibition of I(Ba) amplitude, to an extent comparable to that seen with extracellular LEV pretreatment (≥1 h). Neither pretreatment nor intracellular application of UCB L060 produced any inhibitory effects on I(Ba) amplitude. These results identify a stereospecific intracellular pathway through which LEV inhibits presynaptic Ca(V) channels; resultant reductions in neuronal excitability are proposed to contribute to the anticonvulsant effects of LEV.
Asunto(s)
Bloqueadores de los Canales de Calcio/farmacología , Canales de Calcio , Líquido Intracelular/efectos de los fármacos , Glicoproteínas de Membrana/fisiología , Proteínas del Tejido Nervioso/fisiología , Piracetam/análogos & derivados , Terminales Presinápticos/efectos de los fármacos , Transducción de Señal/efectos de los fármacos , Animales , Bloqueadores de los Canales de Calcio/metabolismo , Canales de Calcio/metabolismo , Líquido Intracelular/metabolismo , Levetiracetam , Ligandos , Masculino , Glicoproteínas de Membrana/metabolismo , Proteínas del Tejido Nervioso/metabolismo , Piracetam/metabolismo , Piracetam/farmacología , Terminales Presinápticos/fisiología , Ratas , Ratas Wistar , Transducción de Señal/fisiología , Ganglio Cervical Superior/efectos de los fármacos , Ganglio Cervical Superior/metabolismoRESUMEN
INTRODUCTION: Antiepileptic drugs are prescribed to patients of all ages and are commonly prescribed to patients over the age of 65. When prescribing these drugs to patients of this age bracket, treatment should be based not only on the diagnosis and seizure type but also on the propensity of the drugs for adverse effects and their drug-drug interactions. AREAS COVERED: This article reviews antiepileptic drugs currently used for treating the elderly and highlights the adverse effects and potential drug-drug interactions for these treatments. The article was complied through literature searches of the Cochrane database of systematic reviews, MEDLINE and SCindeks. EXPERT OPINION: In elderly patients who have hepatic diseases, antiepileptic drugs that are not metabolized in the liver, such as levetiracetam, are preferred; in patients with moderate and severe renal failure, carbamazepine and valproic acid are the preferred antiepileptic drugs. Phenytoin, fosphenytoin, carbamazepine, oxcarbazepine and lamotrigine should not be prescribed in elderly patients with cardiac conduction abnormalities or a history of ventricular arrhythmia. While the majority of antiepileptic drugs interact with other drugs, hepatic enzymes and plasma proteins, a few newer antiepileptic drugs are free from such interactions (e.g., gabapentin, levetiracetam and tiagabine), which make them suitable candidates for elderly patients. However, in order to make further recommendations regarding the choice and dosing regimens of antiepileptic drugs in elderly patients, more extensive clinical research in this specific population is necessary.